CNSP: CNS Pharmaceuticals, Inc. insider trading, 5% holders and institutional ownership
From public SEC filings: open-market insider purchases and sales (Form 4, last 180 days), holders of 5% or more (Schedules 13D and 13G) and institutional ownership (Form 13F). Insider and 5% data delayed 48 hours.
Insider trading
0 open-market buys totaling - and 0 sales totaling - in the last 180 days.
Activist and 5% holders
| Filed | What | Holder | Stake | Change | Filing |
|---|---|---|---|---|---|
| 2026-08-14 | 13G amendment | Ikarian Capital, LLC | 9.90% | SEC |
Institutional ownership (Q2 2026)
11 institutions reported holding $1.34M of CNS Pharmaceuticals, Inc. on Form 13F (11 the quarter before). 4 opened a new position and 4 sold out. Shares held by institutions: +93%.
| Largest holders | Shares | Value |
|---|---|---|
| Ikarian Capital, LLC | 135,830 | $649K |
| ADAR1 Capital Management, LLC | 70,000 | $335K |
| Stonepine Capital Management, LLC | 41,573 | $199K |
| BOOTHBAY FUND MANAGEMENT, LLC | 13,524 | $65K |
| VANGUARD FIDUCIARY TRUST CO | 10,226 | $49K |
| VANGUARD CAPITAL MANAGEMENT LLC | 6,993 | $33K |
| UBS Group AG | 1,461 | $7K |
| Tower Research Capital LLC (TRC) | 799 | $4K |
| BARCLAYS PLC | 19 | $91 |
| BARRETT & COMPANY, INC. | 8 | $38 |
Get new insider and activist filings the morning after: daily alerts. Not investment advice.